А. Н. Махсон

2.2k total citations
23 papers, 1.7k citations indexed

About

А. Н. Махсон is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, А. Н. Махсон has authored 23 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in А. Н. Махсон's work include Cancer Treatment and Pharmacology (16 papers), HER2/EGFR in Cancer Research (8 papers) and Lung Cancer Treatments and Mutations (8 papers). А. Н. Махсон is often cited by papers focused on Cancer Treatment and Pharmacology (16 papers), HER2/EGFR in Cancer Research (8 papers) and Lung Cancer Treatments and Mutations (8 papers). А. Н. Махсон collaborates with scholars based in Russia, United States and France. А. Н. Махсон's co-authors include Paul Bhar, Sergey Cheporov, G. Manikhas, Alicia Clawson, D. Krasnojon, William J. Gradishar, Igor Bondarenko, José Iglesias, Mikhail Lichinitser and Sergei Tjulandin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

А. Н. Махсон

23 papers receiving 1.7k citations

Peers

Countries citing papers authored by А. Н. Махсон

Since Specialization

Citations

This map shows the geographic impact of А. Н. Махсон's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by А. Н. Махсон with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites А. Н. Махсон more than expected).

Fields of papers citing papers by А. Н. Махсон

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by А. Н. Махсон. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by А. Н. Махсон. The network helps show where А. Н. Махсон may publish in the future.

Co-authorship network of co-authors of А. Н. Махсон

This figure shows the co-authorship network connecting the top 25 collaborators of А. Н. Махсон. A scholar is included among the top collaborators of А. Н. Махсон based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with А. Н. Махсон. А. Н. Махсон is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract P4-22-13: Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-1 2017 ·Cancer Research ·Denise A. Yardley, Sara A. Hurvitz, (unknown), Masakazu Toi, Howard A. Burris, Marc Buyse, Dennis J. Slamon, А. Н. Махсон, A. Elsaid, Guillermo Lerzo, Beth A. Hellerstedt, Francesco Nuzzo, Joohyuk Sohn, L. V. Manzyuk, (unknown), Jeremie Lincy, Arved Weimann, (unknown), Lida Pacaud, Fabrice André	3
2	Magnetic Resonance Imaging of the Whole Body (DWIBS). Potentialities and Perspectives for Application in Bone Pathology 2015 ·N N Priorov Journal of Traumatology and Orthopedics ·(unknown), А. Н. Махсон, (unknown)	1
3	Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel, in patients with metastatic breast cancer (MBC) as first-line treatment. 2013 ·Journal of Clinical Oncology ·Young‐Hyuck Im, (unknown), (unknown), Д. В. Комов, (unknown), Sudeep Gupta, Yaroslav Shparyk, Priscilla B. Caguioa, А. Н. Махсон, (unknown), (unknown), (unknown), (unknown), Gia Nemsadze, (unknown), Sang-Joon Lee	30
4	Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer 2013 ·Journal of Clinical Oncology ·Zhongzhen Guan, Binghe Xu, Michelle DeSilvio, Zhenzhou Shen, Wichit Arpornwirat, Zhongsheng Tong, Vicharn Lorvidhaya, Zefei Jiang, Junlan Yang, А. Н. Махсон, (unknown), Mark W. Russo, B. Newstat, Li Wang, George Chen, Cristina Oliva, Henry Gómez	115
5	Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer 2012 ·The Oncologist ·Miguel Martín, А. Н. Махсон, Joseph Gligorov, Mikhail Lichinitser, Aňa Lluch, Semiglazov Vf, Nana Scotto, Lada Mitchell, Sergei Tjulandin	40
6	Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival 2012 ·Clinical Breast Cancer ·William J. Gradishar, D. Krasnojon, Sergey Cheporov, А. Н. Махсон, G. Manikhas, Alicia Clawson, Paul Bhar, John R. McGuire, José Iglesias	91
7	First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study 2012 ·Journal of Clinical Oncology ·Jonas Bergh, Igor Bondarenko, Mikhail Lichinitser, Annelie Liljegren, Richard Greil, (unknown), А. Н. Махсон, Javier Cortés, Alain Lortholary, Joachim Bischoff, Arlene Chan, Suzette Delaloge, Xin Huang, Kenneth A. Kern, C. Giorgetti	206
8	Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial 2012 ·Journal of Clinical Oncology ·Giorgio V. Scagliotti, Maciej Krzakowski, Aleksandra Szczęsna, János Strausz, А. Н. Махсон, Martin Reck, Rafal Wierzbicki, István Albert, Michael Thomas, José Elias Miziara, Zsolt Pápai, Nina Karaseva, Sumitra Thongprasert, E. Dalmau, Joachim von Pawel, Ke Zhang, Paulina Selaru, L. Tye, Richard C. Chao, Ramaswamy Govindan	174
9	Survival results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. 2011 ·Journal of Clinical Oncology ·Mark A. Socinski, Igor Bondarenko, Nina Karaseva, А. Н. Махсон, Ihor Vynnychenko, Isamu Okamoto, Jeremy K. Hon, Vera Hirsh, Paul Bhar, (unknown), J. L. Mesías Iglesias	5
10	A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer 2010 ·Journal of Thoracic Oncology ·Mark A. Socinski, G. Manikhas, (unknown), А. Н. Махсон, Sergey Cheporov, С. В. Орлов, (unknown), Paul Bhar, José Iglesias	67
11	Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer 2010 ·Journal of Clinical Oncology ·Bradley J. Monk, Thomas J. Herzog, Stanley B. Kaye, Carolyn Krasner, Jan B. Vermorken, Franco M. Muggia, Éric Pujade-Lauraine, Alla Lisyanskaya, А. Н. Махсон, Janusz Rolski, Vera Gorbounova, Prafull Ghatage, Mariusz Bidziński, Keng Shen, Hys Ngan, Ignace Vergote, Joo‐Hyun Nam, Youn Choi Park, Claudia Lebedinsky, Andrés Poveda	291
12	Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). 2010 ·Journal of Clinical Oncology ·Mark A. Socinski, Igor Bondarenko, Nina Karaseva, А. Н. Махсон, (unknown), Isamu Okamoto, Jeremy K. Hon, Vera Hirsh, Paul Bhar, José Iglesias	15
13	Development of a new G-CSF product based on biosimilarity assessment 2009 ·Annals of Oncology ·Pere Gascón, Uwe Fuhr, F. Sörgel, M. Kinzig‐Schippers, А. Н. Махсон, Sigrid Balser, Suzanne Einmahl, Michael Muenzberg	77
14	A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer 2009 ·Lung Cancer ·Giorgio V. Scagliotti, Paul Germonpré, Leon Bosquée, Johan Vansteenkiste, R. Gervais, David Planchard, Martin Reck, Filippo de Marinis, Jin Soo Lee, Keunchil Park, Bonne Biesma, Steven Gans, Rodryg Ramlau, A. Szczęsna, А. Н. Махсон, George Manikhas, Bruno Morgan, (unknown), Kai Chio Chan, Joachim von Pawel	48
15	Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer 2009 ·Journal of Clinical Oncology ·William J. Gradishar, D. Krasnojon, Sergey Cheporov, А. Н. Махсон, G. Manikhas, Alicia Clawson, Paul Bhar	260
16	Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer 2008 ·Journal of Clinical Oncology ·José Baselga, Milvia Zambetti, Antonio Llombart‐Cussac, (unknown), E. Kubista, Günther Steger, А. Н. Махсон, Sergei Tjulandin, H Ludwig, Mark Verrill, Eva Ciruelos, Suzanne Egyházi, Lian Xu, Kim E. Zerba, Hye-Rim Lee, Edwin Clark, Susan Galbraith	79
17	Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC) 2007 ·Journal of Clinical Oncology ·Michael Hawkins, G. Manikhas, А. Н. Махсон, Sergey Cheporov, Sergey Orlov, (unknown), Paul Bhar, Mark A. Socinski	5
18	2106 POSTER Randomized clinical comparison of weekly or every-3-week 130-nanometer albumin-bound paclitaxel vs. every-3-week docetaxel as first-line therapy in patients with metastatic breast cancer 2007 ·European Journal of Cancer Supplements ·(unknown), D. Krasnojon, Sergey Cheporov, А. Н. Махсон, (unknown), Alicia Clawson, Michael Hawkins	2
19	Dose escalation study of nab-paclitaxel followed by carboplatin as first line therapy in advanced non-small cell lung cancer (NSCLC) 2006 ·Journal of Clinical Oncology ·Michael Hawkins, (unknown), А. Н. Махсон, Sergey Cheporov, (unknown), (unknown), Paul Bhar, Mark A. Socinski	7
20	Extralesional resection for tumours of the pelvic bones 1997 ·International Orthopaedics ·А. Н. Махсон	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact